Randomized Clinical Trial
Copyright ©The Author(s) 2022.
World J Clin Cases. Jun 26, 2022; 10(18): 6082-6090
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6082
Table 1 Baseline characteristics of included patients
Variables
Control
Group 1
Group 2
Group 3
χ2
F
P value
ASA grade (II/III)18/218/118/217/21.000
Gender (M/F)12/810/98/1212/72.830.422
Age (yr)62.0 ± 8.865.6 ± 9.557.4 ± 9.662.1 ± 10.91.790.209
BMI (kg/m2)23.8 ± 2.324.3 ± 3.223.9 ± 2.025.3 ± 3.10.910.443
Height (cm)162.5 ± 7.8163.1 ± 6.9165.1 ± 6.1164.1 ± 7.40.390.759
Weight (kg)63.5 ± 11.364.5 ± 8.265.5 ± 9.968.1 ± 9.90.600.623
Course of disease (yr)9.50 ± 4.269.42 ± 3.919.15 ± 4.348.74 ± 4.250.130.942
HbA1c (%)7.34 ± 0.377.34 ± 0.507.49 ± 0.467.46 ± 0.560.530.663
Fasting blood glucose (mmol/L)7.35 ± 2.137.08 ± 1.216.95 ± 0.806.56 ± 1.201.030.386
Control of blood glucose (oral/injection of insulin)16/414/516/417/21.760.568